| Dylan Carroll, | |
|
One Hospital Drive, Suite M562, Columbia, MO 65212 | |
| (573) 884-3233 | |
| (573) 884-5994 |
| Full Name | Dylan Carroll |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | One Hospital Drive, Columbia, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033602172 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2018020009 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dylan Carroll, One Hospital Drive, Suite M562, Columbia, MO 65212 Ph: (573) 884-3233 | Dylan Carroll, One Hospital Drive, Suite M562, Columbia, MO 65212 Ph: (573) 884-3233 |
News Archive
Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.
Continua Health Alliance championed the use of personal connected healthcare technologies to increase veteran access to quality healthcare during last week's hearing of the House Committee on Veterans Affairs Subcommittee on Health. President and Chair of the Continua Board of Directors, Rick Cnossen, testified on behalf of the Alliance to address the issues facing veterans living in rural areas who typically receive lower quality healthcare than the general population due to lack of access.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.
› Verified 5 days ago
Rylee Shawn Duckworth, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-4400 Fax: 573-884-5994 | |
Dr. Michael Habhab, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr Emergency Medicine M562 Dc029.10, Columbia, MO 65212 Phone: 573-884-4400 | |
Michael Hauan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1600 E Broadway, Columbia, MO 65201 Phone: 573-815-3573 Fax: 314-631-4491 | |
Derek G Hebert, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-882-6003 Fax: 573-884-5410 | |
Dr. Betsy Lynn Borsheski, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-882-8091 Fax: 573-884-1902 | |
Beth Kreutzer, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr # Dc029.10, Columbia, MO 65212 Phone: 573-884-3233 |